Table 1.
Baseline characteristics including podoplanin expression, IDH1 mutation status and peripheral blood parameters in our patient cohort
| Demographics | Patients studied n (% miss.) | Podoplanin +, ++ and +++ (n = 151) | Podoplanin – (n = 62) | P‐value | IDH1 mutant (n = 42) | IDH1 wild‐type (n = 171) | P‐value | |
|---|---|---|---|---|---|---|---|---|
| Median age at study entry | 213 (0%) | 55 [44–66] | 60 [48–68] | 46 [37–56] | <0.0001 | 42 [36–50] | 60 [48–67] | <0.0001 |
| Female sex | 213 (0%) | 79 (37%) | 54 (36%) | 25 (40%) | 0.53 | 17 (40%) | 62 (36%) | 0.61 |
| Body mass index (BMI, kg/m²) | 213 (0%) | 25 [23–28] | 26 [23–28] | 25 [23–27] | 0.53 | 24 [23–27] | 26 [23–28] | 0.25 |
| Newly‐diagnosed malignancy | 213 (0%) | 185 (87%) | 136 (90%) | 49 (79%) | 0.03 | 35 (83%) | 150 (88%) | 0.45 |
| Brain tumor types | 213 (0%) | / | / | / | <0.0001 | / | / | <0.0001 |
| Glioblastoma/sarcoma (WHO IV) | / | 152 (71%) | 124 (82%) | 28 (18%) | / | 18 (12%) | 134 (88%) | / |
| Anaplastic glioma (WHO III) | / | 38 (18%) | 14 (37%) | 24 (63%) | / | 18 (47%) | 20 (53%) | / |
| Low‐grade glioma (WHO II) | / | 10 (5%) | 3 (30%) | 7 (70%) | / | 4 (40%) | 6 (60%) | / |
| Other | 13 (6%) | 10 (77%) | 3 (23%) | / | 2 (15%) | 11 (85%) | / | |
| Laboratory parameters | ||||||||
| Platelet count (G L−1) | 213 (0%) | 240 [194–311] | 227 [186–285] | 286 [241–355] | <0.0001 | 297 [244–338] | 232 [190–289] | 0.0004 |
| D‐dimer μg mL−1 | 190 (11%) | 0.7 [0.3–1.4] | 0.8 [0.5–1.9] | 0.4 [0.2–0.8] | <0.0001 | 0.4 [0.3–0.8] | 0.7 [0.4–1.7] | 0.008 |
| Soluble P‐selectin, ng mL−1 | 197 (8%) | 37 [29–49] | 37 [29–48] | 39 [29–51] | 0.51 | 37 [29–49] | 38 [29–50] | 0.91 |
| Peak thrombin generation, nm | 212 (0%) | 347 [184–543] | 374 [198–552] | 284 [167–493] | 0.12 | 280 [163–490] | 363 [190–551] | 0.23 |
| Serum calcium (total), mmol L−1 | 124 (42%) | 2.37 [2.27–2.46] | 2.36 [2.25–2.44] | 2.37 [2.31–2.50] | 0.05 | 2.40 [2.31–2.50] | 2.36 [2.26–2.44] | 0.09 |
| Serum calcium (albumin corrected), mmol L−1 | 124 (42%) | 2.31 [2.27–2.38] | 2.32 [2.27–2.39] | 2.30 [2.23–2.36] | 0.15 | 2.28 [2.22–2.37] | 2.32 [2.27–2.39] | 0.06 |
Median levels [25th–75th percentile] are given for continuous data and absolute frequencies (%) for count data. P‐values for the comparison between podoplanin‐positive and podoplanin‐negative tumors, as well as between IDH1 wild‐type and IDH1 mutation, are reported.